World

Mansour bin Zayed attends second day of Zayed Grand Prize Camel Race 2023

Nov 27, 2023

Abu Dhabi [UAE], November 27: His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister and Chairman of the Presidential Court, witnessed the second day of the Zayed Grand Prize Camel Race 2023, which was dedicated to 'Al-Haqayeq' category, at the Al Wathba camel racing track this evening.
The race was also attended by Sheikh Sultan bin Hamdan Al Nahyan, Adviser to the UAE President and Chairman of the UAE Camel Racing Federation, Sheikh Rashid bin Hamdan bin Mohammed Al Nahyan, Chairman of the Board of Directors of the Presidential Flight Authority, and Ali Mohammed Hammad Al Shamsi, the Secretary-General of the Supreme Council for National Security.
His Highness Sheikh Mansour had attended a luncheon hosted by Sheikh Sultan bin Hamdan bin Mohammed Al Nahyan at his rest-house in Al Wathba, in the presence of a large crowd of fans and followers of camel racing from the UAE and GCC states.
The participants in the competitions lauded the unwavering support extended by the UAE wise leadership for this deeply rooted heritage sport. They also expressed gratitude for the prestigious prizes that have elevated camel racing's status to become one of the nation's most esteemed sporting disciplines.
They extended their heartfelt appreciation to H.H. Sheikh Mansour for his boundless support for camel racing and commended his constant presence at various relevant competitions.
Source: Emirates News Agency

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025